About CanTar®
Our Team is about Focused Performance
CanTar., Discover For Pharma® aims to provide professional pathology services covering early research and discovery, preclinical, translational, and clinical development of cancer biomarkers, utilizing cancer cell lines, animal models, and human FFPE samples. The chief consultant pathologist is focused on serving pharmaceutical pipeline needs, with a particular focus on ADC therapeutics, Bispecifics, SMI, ICI, Targeted Protein Degraders (TPD), and radioligands. Our chief consultant pathologist brings extensive experience to our team, having contributed to more than 100 unique target-biomarker development projects in collaboration with multidisciplinary teams over the past 15 years. Our background includes work at leading academic institutions, contract research organizations (CROs), and pharmaceutical companies, positioning us to advance our initiatives effectively. See our proven expertise in cancer targets and disease area expertise.
Every scientific and technical expertise (from project design to image analysis) is conducted personally by the board-certified pathologist without intermediaries.
CanTar Commitment and Work Ethic
The timeline from the NDA to the consultant agreement is firmly established at 7 business days.
For biomarker projects, the turnaround time is guaranteed to be under 30 calendar days (STEALTH).
CanTar Promise: Cancer Target Discovery for Pharma
CanTar promises to deliver accurate and reliable data and translational pathology expertise. CanTar provides precise and reliable data, along with expert translational pathology services, specifically tailored for the pharmaceutical industry. Our commitment to accuracy ensures that our clients can trust the information we provide. Cancer Target Discovery for the pharmaceutical industry.